Similar articles

• Unique antithymocyte serum versus OKT3 for induction immunotherapy after heart transplantation.

  Frist WH, Merrill WH, Eastburn TE, Atkinson JB, Stewart JR, Hammon JW Jr, Bender JW Jr. Frist WH, et al. J Heart Transplant. 1990 Sep-Oct;9(5):489-94. J Heart Transplant. 1990. PMID: 2121921 Clinical Trial.
• Immunosuppressive drugs used in clinical renal transplantation.

  Chatterjee SN. Chatterjee SN. Urology. 1977 Jun;9(6 Suppl):52-60. Urology. 1977. PMID: 70101 No abstract available.
• Single center randomized trial using ATG v OKT3 treatment in steroid resistant rejection crises after kidney transplantation.

  Blümke M, Kirste G, Wanner U, Wilms H. Blümke M, et al. Transplant Proc. 1989 Feb;21(1 Pt 2):1747. Transplant Proc. 1989. PMID: 2652571 Clinical Trial. No abstract available.
• Early rejection prophylaxis in heart transplantation: is cytolytic therapy necessary?

  Renlund DG, O'Connell JB, Bristow MR. Renlund DG, et al. J Heart Transplant. 1989 May-Jun;8(3):191-3. J Heart Transplant. 1989. PMID: 2661767 Review. No abstract available.
• Control of rejection of transplanted organs.

  Keown PA, Stiller CR. Keown PA, et al. Adv Intern Med. 1986;31:17-46. Adv Intern Med. 1986. PMID: 3511616 Review. No abstract available.